Aller au contenu principal
Retour à l'annuaire
MT
RhumatologueMédecins généralistes et spécialistes👤 Libéral intégral

M. Docteur MICHEL TRABIS

📍 Cabestany (66)Libéral💶 Secteur 1RPPS 10003241436

✨ Profil synthétique

IA · 06/05/2026

Le Dr Michel Trabis est un rhumatologue exerçant à Cabestany. Ses publications sur PubMed couvrent divers aspects de la rhumatologie, notamment les revues générales, la pédiatrie, les méta-analyses, l'épidémiologie, les essais cliniques et la pharmacovigilance. Cette variété de sujets suggère une approche globale de la discipline.

Expertises présumées

  • Rhumatologie pédiatrique
  • Épidémiologie des maladies rhumatismales
  • Essais cliniques en rhumatologie
  • Pharmacovigilance en rhumatologie
  • Revue et analyse de la littérature médicale
  • Méta-analyse en rhumatologie

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

Tarifs & secteur de conventionnement

🟢 Secteur 1 — Tarif conventionnéSource CNAM (Annuaire santé Ameli)
💳 Carte VitaleLibéral intégral
📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Ultra-high resolution photon-counting detector coronary CT angiography: diagnostic accuracy in patients with high Agatston scores

    European radiology · 2026

    📚 2 citations🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Abstract Objectives Severe coronary artery calcification leads to blooming artifacts in conventional coronary CT angiography (CCTA), which may reduce diagnostic accuracy. Ultra-high resolution (UHR) photon-counting detector CT (PCD-CT) reduces calcium blooming. This study aimed to evaluate the diagnostic performance of UHR CCTA with PCD-CT for detecting coronary stenoses in patients with a high coronary calcium burden compared to invasive coronary angiography (ICA). Materials and methods In this IRB-approved single-center study, patients with Agatston scores > 600 were included, who underwent ICA and coronary UHR PCD-CT angiography within 2 months. 94% of patients underwent CT prior to transcatheter aortic valve replacement. Coronary arteries were graded for diameter stenosis severity (> 50, > 70%) by two blinded, independent readers. Accuracy, sensitivity, and specificity of CCTA were calculated using ICA as the reference standard. Subgroup analyses were performed across Agatston score groups (600–999, 1000–1999, 2000–2999, and > 3000). Results 62 patients (mean age, 76 ± 9 years, 16 women) were included. The median Agatston score was 2423 (IQR: 1085–3340). Across all Agatston categories, CCTA demonstrated high diagnostic accuracy and strong agreement with ICA (Cohen’s kappa 0.71–1.00). In patients with Agatston scores > 3000 ( n = 18), the diagnostic performance of coronary UHR PCD-CT angiography for detecting > 50% (sensitivity 92–100%, specificity 83–100%) and > 70% diameter stenosis (sensitivity 88–100%, specificity 89–100%) remained high for both readers. There was no correlation between the Agatston score and diagnostic error ( p > 0.05). Conclusion UHR CCTA with PCD-CT provides high diagnostic performance even in patients with extensive coronary calcifications. Key Points Question In patients with severe coronary calcification, conventional coronary CT angiography often suffers from blooming artifacts, reducing accuracy and causing unnecessary invasive procedures. Findings Ultra-high resolution coronary angiography with photon-counting detector CT showed high sensitivity and specificity for detecting stenoses, even at Agatston scores > 3000. Clinical relevance Ultra-high resolution coronary CT angiography enables accurate noninvasive detection of stenoses in heavily calcified vessels, potentially reducing invasive coronary angiography. Graphical Abstract

  • 2
    Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

    The Journal of clinical endocrinology and metabolism · 2026

    📚 2 citations🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Abstract Context Interleukin (IL)-17, a key proinflammatory cytokine, drives inflammation and fibrosis in Graves orbitopathy (GO), and elevated IL-17 and Th17 cells correlate with disease activity and severity. Objective The ORBIT study aimed to evaluate the efficacy and safety of secukinumab, an IL-17A inhibitor, in individuals with active, moderate-to-severe GO. Methods A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial was conducted. Adults with active, moderate-to-severe, non-sight–threatening GO randomly (1:1) received secukinumab 300 mg or placebo subcutaneously over a 16-week double-blind treatment period, followed by an additional 16-week open-label treatment phase for proptosis nonresponders. Safety parameters, thyroid-related hormones, and autoantibodies were also assessed. The primary end point was overall response of reduced Clinical Activity Score (CAS) of 2 or more points and a reduction of 2 mm or greater in proptosis from baseline without worsening in the fellow eye at week 16. Results Twenty-eight adult GO patients with a CAS of 4 or greater were enrolled (secukinumab, n = 14; placebo, n = 14). None in either the secukinumab or placebo group achieved an overall response at weeks 16 and 32, respectively, when all patients received open-label secukinumab. No clinically meaningful changes were observed in ophthalmic symptoms and signs, proptosis, lid aperture, eye muscle motility, CAS, and health-related quality of life either at week 16 or week 32. No meaningful effect on serum levels of thyroid-related hormones and antibodies was observed. Secukinumab was well tolerated, with mostly mild adverse events. Neither treatment-induced study discontinuation nor new safety signals were registered. Conclusion Secukinumab did not show clinical efficacy vs placebo when treating patients with active, moderate-to-severe GO.

  • 3
    Epstein-Barr virus orchestrates spatial reorganization and immunomodulation in the classic Hodgkin lymphoma tumor microenvironment

    Cell reports. Medicine · 2026

    📚 2 citations🔓 Open Access

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal26

▼

Revue générale8

▼

Pédiatrie5

▼

Revue / méta-analyse5

▼

Épidémiologie & registres3

▼

Essai clinique3

▼

Pharmacovigilance3

▼

Vraie vie / RWE3

▼

Anti-IL-171

▼

Gériatrie1

▼

Microbiote1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.